Management of advanced colorectal cancer, part 2

American Journal of Health-System Pharmacy

Volumn 70, Issue 6, 2013, Pages 491-506

  Cersosimo, Robert J ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; REGORAFENIB;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG TOLERABILITY; DRUG TOXICITY; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; ONCOGENE K RAS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; ULCER; WOUND COMPLICATION;

EID: 84875536112     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110532b     Document Type: Review

References (84)

1. Avastin (bevacizumab) prescribing information. South San Francisco, CA: Genentech; 2011 Feb.
2. Erbitux (cetuximab) prescribing information. Indianapolis, IN: Eli Lilly and Co.; 2012 Dec.
3. Vectibix (panitumumab) prescribing information. Thousand Oaks, CA: Amgen; 2012 Aug.
4. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2007; 26:689-90. Letter.
5. Sobrero A, Ackland S, Clarke S et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009; 77: 113-9.
6. Kopetz S, Hoff PM, Morris JS et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010; 28:453-9.
7. Giuliani F, de Vita F, Lorusso V et al. FOLFIRI + bevacizumab as first-line treatment in advanced colorectal cancer (ACC): final results (prot. GOIM 2601). J Clin Oncol. 2009; 27(suppl):abstract e15007.
8. Ruiz de Lobera A, Moreno A, Sancho A et al. First-line treatment with FOLFIRI- bevacizumab for advanced colorectal cancer (ACRC): a single institution experience with 77 consecutive unselected patients. Amer Soc Clin Oncol Gastrointest Cancers Symp. 2008; abstract 494.
9. Smith D, Rouyer M, Becouarn Y et al. Effectiveness and safety of bevacizumab plus FOLFIRI in first-line metastatic colorectal cancer (mCRC) after 24 months of follow-up for the ETNA cohort study. J Clin Oncol. 2010; 28(suppl):abstract e14075.
10. Ducreux M, Adenis A, Mendiboure J et al. Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study). J Clin Oncol. 2009; 27(suppl):abstract 4086.
11. Ziras N, Polyzos A, Xenidis N et al. CAPIRI plus bevacizumab (CAPIRIB) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2010; 28(suppl):abstract 3542.
12. Pectasides DG, Xanthakis I, Makatsoris T et al. Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil-leucovorin (FOLFIRI) plus bevacizumab as firstline treatment in patients with metastatic colorectal cancer: a randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG). J Clin Oncol. 2010; 28(suppl):abstract 3541.
13. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26:2013-9.
14. Bendell JC, Fernando N, Morse M et al. A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer. Proc Amer Soc Clin Oncol. 2006; 24(suppl 18S):260S, abstract 3541.
15. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX 4) for previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol. 2007; 25:1539-44. (Pubitemid 46733080)
16. Raoul JL, van Laethem JL, Peeters M et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicenter two-part phase I/II study. BMC Cancer. 2009; 9:112.
17. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29:2011-9.
18. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360:1408-17.
19. Koo DH, Lee JL, Kim TW et al. A phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatinrefractory metastatic colorectal cancer. J Korean Med Sci. 2007; 22(suppl): S98-103.
20. Tabernero J, van Cutsem E, Diaz Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007; 25:5225-32. (Pubitemid 350232254)
21. Colucci G, Giuliani F, Garufi C et al. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale phase II study. Oncology. 2010; 79:415-22.
22. Boccia RV, Cosgriff TM, Headley DL et al. A phase II trial of FOLFOX 6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010; 9:102-7.
23. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27:663-71.
24. Yuan Y, Ma H, Cohen J et al. Activity and tolerance of biweekly CapeOxcetuximab in 1st line therapy of metastatic colorectal cancer (mCRC): relation to K-ras mutation status. J Clin Oncol. 2009; 27(suppl):abstract e15018.
25. Barroso SA, Sanches E, Ferreira M et al. Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): results of a phase II study. J Clin Oncol. 2009; 27(suppl):abstract e15013.
26. Souglakos J, Kalykaki A, Vamvakas L et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatinbased chemotherapy. Ann Oncol. 2007; 18:305-10. (Pubitemid 46323098)
27. Maughan TS, Adams R, Smith CG et al. Addition of cetuximab to oxaliplatinbased first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet. 2011; 377:2103-14.
28. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360:563-72. [Erratum, N Engl J Med. 2010; 363:2573.].
29. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25:1658-64. (Pubitemid 46797944)
30. Douillard JY, Siena S, Cassidy J et al. Randomized phase III study of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX 4) versus FOLFOX 4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28:4697-705.
31. Douillard J, Siena S, Cassidy J et al. Final results from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). J Clin Oncol. 2011; 29(suppl):abstract 3510.
32. Kohne C, Mineur L, Greil R et al. Primary analysis of a phase II study (20060314) combining first-line panitumumab (pmab) with FOLFIRI in the treatment of patients (pts) with metastatic colorectal cancer (mCRC). Poster presented at 2010 Gastrointestinal Cancers Symposium. Chicago, IL; 2010 Jun.
33. Hecht JR, Patnaik A, Berlin J et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007; 110:980-8. (Pubitemid 47312862)
34. Muro K, Yoshino T, Doi T et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2009; 39:321-6.
35. Resch G, Schaberl-Moser R, Kier P et al. Analysis of the Austrian compassionate use program of panitumumab (pmab) in patients (pts) with metastatic colorectal cancer (mCRC). Poster presented at 2009 Gastrointestinal Cancers Symposium. San Francisco, CA; 2009 Jun.
36. Van Cutsem E, Siena S, Humblet Y et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008; 19:92-8.
37. Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28:4706-13.
38. Cohn AL, Smith DA, Neubauer MA et al. Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI. J Clin Oncol. 2008; 26(May suppl):abstract 4127.
39. Chibaudel B, Tournigand C, Mabro M et al. Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: a GERCOR study. J Clin Oncol. 2011; 29(suppl):abstract 3573.
40. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005; 23:3502-8.
41. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335-42. (Pubitemid 38702844)
42. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil- leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005; 23:3706-12.
43. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI, and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009; 20:1842-7.
44. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009; 14:862-70.
45. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008; 26:5326-34.
46. Cao Y, Tan A, Gao F et al. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009; 24:677-85.
47. Masi G, Loupakis F, Salvatore L et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010; 11:845-52.
48. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27:2091-6.
49. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359:1757-65.
50. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008; 26:374-9. (Pubitemid 351171687)
51. De Roock W, Piessevaux H, de Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008; 19:508-15. (Pubitemid 351325672)
52. Qiu LX, Mao C, Zhang J et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a metaanalysis of 22 studies. Eur J Cancer. 2010; 46:2781-7.
53. Amado RG, Wolf M, Peters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26:1626-34.
54. Pessino A, Artale S, Sciallero S et al. Firstline single agent cetuximab in patients with advanced colorectal cancer. Ann Oncol. 2008; 19:711-6. (Pubitemid 351467382)
55. Bokemeyer C, Bondarenko I, Hartmann JT et al. Biomarkers predictive of outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX 4 plus or minus cetuximab: updated data from the OPUS study. Proc Amer Soc Clin Oncol Gastrointest Cancer Symp. 2010; abstract 428.
56. Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration. Oncologist. 2008; 13:113-9. (Pubitemid 351342574)
57. Shitara K, Yuki S, Yoshida M et al. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Invest New Drugs. 2012; 30:787-93.
58. Martin-Martorell P, Rosello S, Rodriguez- Braun E et al. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer. 2008; 99:455-8.
59. Pfeiffer P, Nielsen D, Bjerregaard J et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin, and 5-fluorouracil. Ann Oncol. 2008; 19:1141-5. (Pubitemid 351796340)
60. Tahara M, Shirao K, Boku N et al. Multicenter phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Jpn J Clin Oncol. 2008; 38:762-9.
61. Vincenzi B, Santini D, Rabitti C et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer. 2006; 94:792-7.
62. Wilke H, Glynne-Jones R, Thaler J et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study. J Clin Oncol. 2008; 26:5335-43.
63. Lim R, Sun Y, Im SA et al. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. World J Gastroenterol. 2011; 17:1879-88.
64. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Amer Soc Clin Oncol. 2001; 20:abstract 7.
65. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidines and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26:2311-9.
66. Gamucci T, Nelli F, Cianci G et al. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. Clin Colorectal Cancer. 2008; 7:273-9.
67. Ciuleanu T, Nikolic V, Shmueli E et al. Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). J Clin Oncol. 2011; 29(suppl):abstract 3580.
68. Saltz LB, Lenz HJ, Kindler HL et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007; 25:4557-61. (Pubitemid 350035312)
69. Segal NH, Reidy-Lagunes D, Capanu M et al. Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumabcontaining regimen (the BOND 2.5 study). J Clin Oncol. 2009; 27(suppl): abstract 4087.
70. Hecht JR, Mitchell E, Chidiac T et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009; 27:672-80.
71. Amgen Inc. Amgen discontinues Vectibix treatment in PACCE trial evaluating Vectibix as part of triple combination regimen (March 22, 2007). www.amgen.com/media/media-pr-detail.jsp?releaseID=977186 (accessed 2012 Dec 18).
72. Oostendorp LJ, Stalmeier PF, Paskerde Jong PC et al. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. Anti-Cancer Drugs. 2010; 21:749-58.
73. Arnold D, Andre T, Bennouna J et al. Bevasiczumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). Proc Amer Soc Clin Oncol. 2012; abstract CRA3503.
74. Cartwright TH, Yim YM, Yu E et al. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer. 2012; 11:238-46.
75. Lenz HJ, van Cutsem E, Khambata- Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. J Clin Oncol. 2006; 24:4914-21. (Pubitemid 46630920)
76. Wierzbicki R, Jonker DJ, Moore MJ et al. A phase II multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs. 2011; 29:167-74.
77. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22:1201-8. (Pubitemid 41079832)
78. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357:2040-8. (Pubitemid 350106711)
79. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med. 2004; 351:337-45. (Pubitemid 38944402)
80. Giusti RM, Shastri K, Pilaro AM et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinomas with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res. 2008; 14:1296-302. (Pubitemid 351413907)
81. Zaltrap (ziv-aflibercept) prescribing information. Bridgewater, NJ: Regeneron Pharmaceuticals, Inc. and sanofi-aventis U.S.; 2012 Aug.
82. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30:3499-506.
83. Stivarga (regorafenib) prescribing information. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc.; 2012 Sep.
84. Grothey A, Sobrero AF, Siena S et al. Results of a phase III randomized, doubleblind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Proc Amer Soc Clin Oncol. 2012; abstract 87795.